A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features

Trial Profile

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms RESOLVE-1
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2016 Results of post hoc analysis evaluating the impact of baseline depression severity on treatment response presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 20 Sep 2016 Results of post-hoc analysis, presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top